Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vigil Neuroscience, Inc. (VIGL : NSDQ)
 
 • Company Description   
Vigil Neuroscience Inc. is a microglia-focused therapeutics company. It focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil Neuroscience Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 75

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.10 Daily Weekly Monthly
20 Day Moving Average: 28,736 shares
Shares Outstanding: 35.69 (millions)
Market Capitalization: $360.42 (millions)
Beta: 3.34
52 Week High: $16.77
52 Week Low: $2.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 12.98% 8.70%
12 Week -15.06% -21.15%
Year To Date -19.20% -26.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 FORGE ROAD SUITE 700
-
WATERTOWN,MA 02472
USA
ph: 857-254-4445
fax: -
scarmody@vigilneuro.com http://www.vigilneuro.com
 
 • General Corporate Information   
Officers
Ivana Magovcevic-Liebisch - Chief Executive Officer and President
Bruce Booth - Chairman
Jennifer Ziolkowski - Chief Financial Officer
Cheryl Renee Blanchard - Director
Gerhard Koenig - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92673K108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/14/23
Share - Related Items
Shares Outstanding: 35.69
Most Recent Split Date: (:1)
Beta: 3.34
Market Capitalization: $360.42 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.22 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.10
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 12.07%
vs. Previous Quarter: -6.25%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/23 - -40.60
12/31/22 - -38.38
09/30/22 - -55.45
ROA
03/31/23 - -37.99
12/31/22 - -36.59
09/30/22 - -38.74
Current Ratio
03/31/23 - 23.30
12/31/22 - 17.49
09/30/22 - 22.19
Quick Ratio
03/31/23 - 23.30
12/31/22 - 17.49
09/30/22 - 22.19
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Book Value
03/31/23 - 4.80
12/31/22 - 5.31
09/30/22 - 7.28
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©